Internal Medicine, Hematology & Oncology · Boston, MA
NPI
1134104920
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
44 Binney St, Dana-Farber Cancer Institute
Boston, MA, 02115
Phone (617) 632-2645
Groups this clinician bills Medicare through
Medicare paid, 2024
$56K
728 services
Medicare patients, 2024
251
Average age 75
Drug cost, 2024
$7.0M
887 prescriptions
Company payments, 2025
$40K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel J Deangelo was code 99214 (office e&m - established), 298 times for 137 patients. In total Daniel J Deangelo billed 728 services in 16 codes, and Medicare paid $56K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 298 | 137 | $75.66 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 196 | 33 | $65.43 | $13K |
| 99213 Office E&M - Established | Facility | 88 | 68 | $50.00 | $4,400 |
| 99205 Office E&M - New | Facility | 40 | 40 | $142.73 | $5,709 |
| 99215 Office E&M - Established | Facility | 31 | 25 | $119.08 | $3,692 |
| 99443 Telephone Services | Facility | 25 | 16 | $72.86 | $1,821 |
| 99239 Hospital Discharge Management | Facility | 15 | 15 | $95.74 | $1,436 |
By year: 2022 $61K for 726 services; 2023 $64K for 790 services; 2024 $56K for 728 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel J Deangelo prescribed most often to Medicare patients was Hydroxyurea, with 109 prescriptions and refills. In total Daniel J Deangelo wrote 887 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 109 | 284 | 29 | $2,769 |
| Jakafi Ruxolitinib Phosphate | 103 | 103 | 17 | $1.6M |
| Imatinib Mesylate Generic | 80 | 80 | Under 11 | $173K |
| Ayvakit Avapritinib | 51 | 51 | Under 11 | $2.0M |
| Sprycel Dasatinib | 42 | 42 | Under 11 | $503K |
| Venclexta Venetoclax | 27 | 27 | Under 11 | $202K |
| Prednisone Generic | 26 | 66 | Under 11 | $210 |
| Scemblix Asciminib Hydrochloride | 22 | 22 | Under 11 | $439K |
| Deferasirox Generic | 19 | 19 | Under 11 | $3,444 |
| Allopurinol Generic | 19 | 43 | Under 11 | $184 |
| Vonjo Pacritinib Citrate | 18 | 18 | Under 11 | $402K |
| Acyclovir Generic | 18 | 50 | Under 11 | $436 |
| Lorazepam Generic | 17 | 17 | Under 11 | $98.4 |
| Tibsovo Ivosidenib | 12 | 12 | Under 11 | $352K |
| Furosemide Generic | 12 | 32 | Under 11 | $115 |
Brand drugs: 358 claims; generic drugs: 529 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel J Deangelo $40K ($37K in general payments such as food, travel and fees and $3,047 for research) from 18 companies. The largest payer was Pfizer Inc. with $7,780.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 6 | $7,780 |
| Autolus Inc | 1 | $6,635 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $5,814 |
| Geron Corporation GERN | 5 | $3,491 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $3,400 |
| Sobi, Inc SOBI.ST | 1 | $2,775 |
| Servier Pharmaceuticals LLC | 1 | $2,720 |
| Syndax Pharmaceuticals, Inc. SNDX | 2 | $2,408 |
| Adaptive Biotechnologies Corporation ADPT | 1 | $2,400 |
| Merck Sharp & Dohme LLC MRK | 1 | $2,240 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.